From the Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, Ontario, Canada (ANH, NB, BLF); Department of Psychiatry, King AbdulAziz University, Jeddah, Saudi Arabia (ANH); Department of Pharmacology and Toxicology, Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada (ANH, BLF); Department of Psychiatry, Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada (ANH, BLF); Institute of Medical Sciences, University of Toronto, Toronto, Ontario, Canada (ANH, BLF); Department of Family and Community Medicine, University of Toronto, Toronto, Ontario, Canada (NB, BLF); Department of Psychiatry and Addictology, Faculty of Medicine, Université de Montréal, Montréal, Québec, Canada (DJ-A); Research Centre, Centre Hospitalier de l'Université de Montréal, Montréal, Québec, Canada (DJ-A); British Columbia Centre on Substance Use, Vancouver, British Columbia, Canada (MES); Department of Medicine, Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada (MES); Department of Psychiatry, Dalhousie University, Veterans' Memorial Lane, Halifax, Nova Scotia, Canada (SHS); Department of Psychology and Neuroscience, Dalhousie University, Life Sciences Centre, Halifax, Nova Scotia, Canada (SHS); Department of Medicine and Psychiatry, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada (RL); Waypoint Research Institute, Waypoint Centre for Mental Health Care, Penetanguishene, Ontario, Canada (BLF).
Received for publication April 14, 2022; Revised June 7, 2022.
Supported by the Canadian Institutes of Health Research through the Canadian Research Initiative in Substance Misuse (grant numbers CIS-144301, CIS144302, CIS-144303, and CIS-144304). The 4 nodes of Canadian Research Initiative in Substance Misuse received independent funding through a Canadian Institutes of Health Research priority-driven initiative (grant numbers SMN-139148, SMN-139149, SMN-139150, and SMN139151).
Dr Bernard Le Foll has obtained funding from Pfizer Inc (GRAND Awards, including salary support) for investigator-initiated projects and from Indivior for a clinical trial sponsored by Indivior. He has in-kind donations of cannabis products from Aurora Cannabis Enterprises Inc and study medication donations from Pfizer Inc (varenicline for smoking cessation) and Bioprojet Pharma. He was also provided a coil for a transcranial magnetic stimulation study from Brainsway. Furthermore, Dr Bernard Le Foll has obtained industry funding from Canopy Growth Corporation (through research grants handled by the Centre for Addiction and Mental Health and the University of Toronto), Bioprojet Pharma, Alcohol Countermeasure Systems, Alkermes, and Universal Ibogaine, and he has received in-kind donations of nabiximols from GW Pharmaceuticals for past studies funded by Canadian Institutes of Health Research and National Institutes of Health. Dr Bernard Le Foll has participated in a session of a National Advisory Board Meeting (Emerging Trends BUP-XR) for Indivior Canada and has been consultant for Shinogi. He is supported by Centre for Addiction and Mental Health a clinician-scientist award from the Department of Family and Community Medicine of the University of Toronto, and a chair in Addiction Psychiatry from the Department of Psychiatry of University of Toronto. Dr M. Eugenia Socias has received partial support from Indivior's Investigator Initiated Study program for work outside this study.
Supplemental digital content is available for this article. Direct URL citation appears in the printed text and is provided in the HTML and PDF versions of this article on the journal’s Web site (www.journaladdictionmedicine.com).
Send correspondence to Ahmed N. Hassan, MD, FRCPC, MPH, Department of Psychiatry, Centre for Addiction and Mental Health, 100 Stokes St, Third Floor, Toronto, ON M6J 1H4, Canada. E-mail: [email protected].
